Login to Your Account


PCSK9 dogfight: Amgen wins in phase III results, Regeneron snarls back

By Randy Osborne
Staff Writer

Tuesday, April 1, 2014
With its protein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab showing strong anti-cholesterol results across patient populations and dosing schedules (monthly as well as every two weeks) in phase III trials, Amgen Inc. held fast against data provided thus far by Regeneron Pharmaceuticals Inc. with alirocumab, also targeting PCSK9.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription